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Insulin hexamers1. Introduction
In the 1970s, during a search for naturally occurring molecules
with glucose lowering activity, a partially puriﬁed peptide
preparation was isolated from human urine [17,18]. The active
constituent has been identiﬁed as a tetrapeptide with the amino
acid sequence Gly His Thr Asp amidated at the C terminus
(GHTD amide) [19]. The mechanism of action of this peptide
remains unknown.* Corresponding author at: School of Science and Engineering, University of
Ballarat, University Drive,Mt. Helen, Victoria, 3353, Australia. Tel.: +61 3 53279291;
fax: +61 3 53279240.
E-mail address: m.myers@ballarat.edu.au (M.A. Myers).
Abbreviations: AUC, area under the curve; ITT, insulin tolerance test; ISF402, the
tetrapeptide Val–His–Thr–Asp–amide.Insulin is an allosteric protein that forms hexameric complexes
with zinc ions, which strongly inﬂuence the stability and dynamic
properties of the complex [20,21]. The formation of these
hexamers likely plays critically important roles in the synthesis,
assembly and storage of insulin [23,2,3]. Zinc stabilized hexamers
of insulin must disperse to monomeric form in order to bind to the
insulin receptor to initiate the cascade of protein phosphorylation
that culminates in cellular glucose uptake and storage [8].
Histidine containing peptides like GHTD amide generally bind
zinc ions and some zinc binding molecules can disperse zinc
stabilized insulin hexamers to monomers [24]. This raises the
question of whether dispersal of zinc insulin hexamers plays a role
in insulin potentiation by GHTD amide. The aim of this study was
to characterize the binding of zinc ions by GHTD amide, an analog
called ISF402 (VHTD amide) and the tripeptide HTD amide, test
their ability to disperse hexameric insulin and establish the
contribution of this activity to enhancement of insulin activity in
vivo.
2. Research design and methods
2.1. Peptides
The peptides GHTD amide and ISF402 (VHTD amide) used for
in vivo experiments were synthesized by standard solid phase
Fmoc chemistry (Mimotopes, Clayton, Australia) and isolated as
TFA salts. The peptide VHTD amide (acetate salt) used for in vitro
studies was synthesized by liquid phase methods (PolyPeptide
Laboratories, CA, USA). HTD amide and the tri /tetrapeptide
analogs Ac HTD amide, VHT amide, Ac VHTD amide, VHTD OH,
VVTD amide, VHTN amide, VHAD amide, DTHV amide, GHTD
amide, ARSE amide, GHSE amide were all synthesized by solid
phase Fmoc chemistry as TFA salts (GL Biochem, Shanghai, China).
Bovine hexameric zinc insulin and recombinant (rec ) human
insulin were purchased from Sigma (St Louis, MO). Pharmaceutical
grade human insulin (Humalin) was sourced from Eli Lilly (NSW,
Australia).
HTD amide used for potentiometric titration was lyophilized
three times in a 2:1 solution of 0.05N HCl(aq) and acetonitrile to
remove TFA [1]. HPLC standard curves were generated for VHTD
amide, HTD amide, and VVTD amide from batches of known
peptide content using a Shimadzu 10AT VP System equipped with
a PDA detector (214 nm) and a Phenomenex Luna(2) C 18 column,
250 mm  4.6 mm. All peptide samples were eluted with a 20 min
gradient of 0 25% acetonitrile; both water and acetonitrile mobile
phases contained 0.1% (v/v) TFA. The concentrations of stock
solutions of other analogs were determined from the standard
curves of HTD amide, VHTD amide, or VVTD amide (whichever
was most chemically similar) and corrected by a ratio of the
theoretical molar extinction coefﬁcients for the standard peptide
and the peptide of unknown concentration [14]. All measurements
were corrected for peptide content.
2.2. Ion Trap Electro Spray Ionization Mass Spectrometry
Mass spectrometry was performed using a Bruker 1200 series
Ion Trap Electro Spray Mass Spectrometer, and all spectra were
recorded in the positive ion mode with voltages less than 30 V to
minimize destruction of peptide Zn2+ ion adducts. For all
experiments, a 5 mM ammonium acetate buffer system was used
and adjusted to pH 7.0. Peptide and zinc(II) nitrate stocks
(prepared using Zn(NO3)2 6H2O) were also adjusted to pH 7.0.
Samples were measured within 48 h of preparation and no
difference in spectral patterns was observed between samples
measured 1 h or 1 day after preparation. Degassed 18.2 MVwater
was the most satisfactory solvent for these analyses as it yielded
the cleanest spectra.
2.3. Circular dichroism
All Circular dichroism (CD) measurements were performed at
25 8C on Jasco J 810 or J 815 spectropolarimeters equipped with a
PFD 423S/L Peltier type temperature controller. For far UV
peptide Zn2+ binding experiments, the instrument bandwidth
was set at 1.0 nm and scans across 190 250 nm were averaged
across 5 accumulations at 50 nm/min. For near UV experiments to
study the effects of Zn2+ binding peptides on insulin aggregation,
the instrument bandwidth was set at 2.0 nm and scans across the
250 300 nm range were averaged for 5 accumulations at 50 nm/
min. The diluents in all CD experiments was freshly prepared,
ﬁltered and degassed 20 mM Tris HCl, pH 7.0. All spectra were
corrected for background.2.4. Peptide far UV CD
All peptide analogswere screened for Zn2+ binding in the far UV
(190 250 nm) using a 600ml, 2 mm path length quartz cuvette.
Each peptide (100mM) was scanned in the absence and presence
of 200 mM Zn2+. Zinc binding was revealed by any signiﬁcant
increase in the negative ellipticity at 220 nmupon addition of Zn2+.
Such changes in ellipticity were assumed to reﬂect peptide
conformational constraint induced by Zn2+ binding. Furthermore,
changes in ellipticity suggested a saturable binding mode that
would enable comparison of the relative afﬁnities of different
peptide analogs for Zn2+. Measurements were performed in
ultrapure water at a pH of 7.4.
The peptides GHTD amide, VHTD amide and HTD amide were
selected for Zn2+ titration analysis in the far UV region (190
250 nm) using a 3.5 ml, 10 mm path length cuvette. Assuming 1:1
binding, the concentration of bound zinc ([Zn2+]B) was determined
as a fraction of the peptide concentration (constant) multiplied by
the normalized change in CD for each titration sample. Free zinc
concentration ([Zn2+]F) was then calculated by subtracting [Zn
2+]B
from [Zn2+]T. Non linear regression analysis (single site hyperbolic
binding) was performed on plots of [Zn2+]B vs [Zn
2+]F to yield
estimates of KD, according to Eq. (1):
Y BMAX
X
KD þ X (1)
where BMAX represents maximal binding and KD is the ligand
concentration at which half maximal binding is achieved. All data
analysis was performed using GraphPad Prism Software. Experi
ments were reﬁned to ensure consecutive 2 fold dilutions of the
peptide gave very similar values for KD. This entailed titrating the
lowest peptide concentrations (between 10 and 100 mM) to
eliminate derivation of erroneously high KD values. Overestimation
of KD values was apparent at peptide concentrations greater than
100 mM for VHTD amide/GHTD amide and 50 mM for HTD amide.
Similarly, lower peptide concentrations enabled higher zinc ratios
to be employed, without compromising spectral quality. All
measurements were performed at pH 7.4.
2.5. Insulin far and near UV CD
Humalin (2Zn insulin)was assayed for aggregationusing far UV
(190 250 nm) and near UV (250 300 nm) CD as reported pre
viously for studies of bovine and human insulin [12,5,15] enabling
the effects of zinc binding peptides on insulin hexamer dispersal to
be studied. All experiments were performed using a 1 mm path
length quartz cuvette due to the high protein concentrations
employed. Samples were incubated for 10 min prior to reading to
enable re equilibration of insulin aggregates upon the addition of
zinc binding peptide. Humalin insulin (100mM) was titrated with
HTD amide at ratios of 1:1 and 1:2 insulin:HTD. Comparison of
ellipticity at 275 nm between either insulin alone and HTD titrated
samples revealed changes in the insulin aggregation state.
2.6. Potentiometry
Potentiometric titration of HTD alone and several ratios of
HTD:Zn2+ (1:1, 2:1, 4:1 and 8:1) was performed to verify the
apparent 1:1 and 1:2 HTD:Zn2+ binding stoichiometry detected
using Ion Trap ESI MS. Titrations were performed using a
Metrohm 808 Titrando equipped with a 801 stirrer and 10 ml
reaction vessel; data was collected using Tiamo software v.1.0.
Standardized KOH titrant (0.84 M), KNO3 (1.0 M) and all HTD
amide and zinc nitrate stock solutions were freshly prepared each
day using degassed 18.2 MV resistivity water. The KNO3 solution
was used to adjust the ionic strength of all samples to 0.1 Mprior to
titration analysis. HTDwas used at a ﬁnal concentration of 1 mM in
all samples. Triplicate data sets were generated for HTD alone and
each HTD:Zn2+ ratio. All titrations were performed under a
constant N2(g) stream to prevent CO2 ingress and formation of
bicarbonate ions in reaction solution.
2.7. Insulin hexamer dispersal by size exclusion chromatography
Size exclusion chromatography was used to study the effect of
GHTD amide on hexameric insulin. Recombinant human insulin
solution was diluted to 2 mg/ml with 10 mM Tris pH 7.4 and
dialyzed against 10 mM Tris pH 7.4. This was performed to remove
HEPES from the solution,which absorbs strongly at 214 nmand co
elutes with GHTD amide. An insulin stock solution at 1.5 mg/ml
was then prepared by the addition of phenol to 4 mM, NaCl to
140 mM and ZnCl2 to 100mM. Prior to chromatography the stock
insulin was mixed with either water or test peptide to give a ﬁnal
concentration of 1 mg/ml each of insulin and test peptide where
applicable, and 10 mM Tris pH 7.4, 140 mM NaCl and 100 mM
ZnCl2. The insulin and peptide mixtures were incubated at room
temperature (22  3 8C) for 1 h and then subjected to size exclusion
chromatography using a 1 cm  30 cm Superdex 75 HR 10/30 column
at a ﬂow rate of 0.1 ml min 1 with an eluent comprising Tris buffered
isotonic saline (140 mM NaCl, 10 mM Tris/HCl pH 7.4, 60 mM ZnCl2).
UV absorption of the eluate was measured at 214 and 276 nm, and
0.5 ml fractionswere collected for protein determination. Protein size
standards aprotinin (6 kDa) and carbonic anhydrase (29 kDa) run
under the same conditions eluted at 18.85 and 14.75 ml, respectively.
A non zinc chelating peptide (NCP) with the sequence Ala Arg Ser
Glu amide was used as a negative control.
The gel matrix, which has a fractionation range of 3000
70 000 Da, and the sample volume loaded were chosen to ensure
that the two peptides remained in contact within the gel matrix
thereby allowing interaction to occur between the two during the
separation process. The concentration of insulinwasmaintained at
1 mg/ml at pH 7.4 in the presence of 2Zn2+/hexamer since it has
been shown that at this concentration insulin exists predomi
nantly as Zn2+ dependent hexamers. Under these conditions the
addition of excess EDTA to the insulin solution resulted in the
appearance of a large shoulder on the insulin peak corresponding
to dimeric insulin (data not shown).
2.8. Animals
All experiments were performed according to Monash Uni
versity Animal Care and Ethics Committee guidelines and
approved by the Monash University Animal Ethics Committee.
Zucker fa/fa (ZDF/Asmu) rats were from Monash Animal Services
(Monash University, Victoria, Australia). Sprague Dawley
(Crj:CD(SD)IGS) rats were from the Animal Resource Center
(Canning Vale, Western Australia). ZDF rats were used at 14 20
weeks of age and on average weighed 370  24 g for females and
430  50 g for males. The average weight of the male Sprague
Dawley rats was 464  50 g. Rats were housed in an environmentally
controlled room at 22 8C and allowed to acclimatize for 7 days. Rats
were fed normal chow and water ad libitum.
Prior to the experiment, rats were fasted overnight (16 h).
Sodium pentobarbitone (Nembutal, Phone Merieux, QLD, Austra
lia) was injected intraperitoneally at 35 mg/kg and blood glucose
wasmonitored usingMedisense glucometers (Abbott Laboratories,
Abbott Park, IL). Rats were placed on heat pads while under
pentobarbitone anesthesia to prevent hypothermia. Under these
conditions glucose homeostasis is comparable to unanesthetized
animals [15]. GHTD amide and ISF402 (1.5 mg/kg) and insulin
were dissolved in sterile 0.9% saline and injected through the
femoral vein at the doses indicated. A dose of 1.5 mg/kg waschosen as the optimal dose based on dose ranging studies in Zucker
rats (data not shown). For co injection, peptide was mixed with
hexameric zinc insulin (Sigma, St Louis, MO) just prior to injection.
1 U/kg of insulin was intravenously administered into Zucker rats
and 0.5 U/kg of insulin in Sprague Dawley rats. Intravenous rather
than subcutaneous injection was chosen in order to test the effect
of the peptides on insulin in solution rather than on the rate of
systemic absorption from a subcutaneous injection site [5]. Soluble
insulin concentrations in the injection solutions were not
inﬂuenced by the presence of peptide as shown by optical density
measurement at 260 and 280 nm (data not shown). Whole blood
was collected from the tail vein and blood glucose measured
immediately. Serumwas separated using capiject serum separator
tubes (Terumo, Elkton, MD) and stored at 80 8C for later analysis
of insulin and C peptide using rat insulin and C peptide radio
immunoassay kits (Linco Research Inc., St. Charles, MO).
2.9. Statistical analysis
Where appropriate data were assessed by ANOVA and
Bonferroni post hoc comparisons using GraphPad Prism software.
Area under the curve (AUC) was calculated by the trapezoidal
method and analyzed by Student’s t test.
3. Results
3.1. Zn2+ binding by HTD amide peptides
Mass Spectrometry and circular dichroismwere used to analyze
Zn2+ binding by GHTD amide, ISF402, HTD amide and various
analogs. The tripeptide HTD amide was included because the
amino terminal Gly has been found to be cleaved from GHTD
amide in biological ﬂuids (data not shown) hence the tripeptide
may have biological relevance. Binding to zinc can induce structure
into short peptides that would otherwise be expected to behave
randomly in solution so the effect of zinc ions on the secondary
structure of the peptides was examined using far UV circular
dichroism (Fig. 1A F). The CD proﬁle of ISF402 in the absence of
zincwas typical of random coil with a pronounced negative peak at
198 nm (Fig. 1A). Upon addition of Zn2+ the negative peak
displayed a slight shift to 200 nm and a second negative peak
appeared at 220 nm. Similar results were seen for GHTD amide
(data not shown) and HTD amide (Fig. 1B). No change in CD proﬁle
was observed for ARSE amide, which lacks histidine, and the N
terminally acetylated peptides Ac HTD amide and Ac VHTD
amide showed only small changes in CD proﬁle upon the addition
of Zn2+ (Fig. 1B and D). Similar data for a range of analogs is
summarized in Table 1. The peptides that formed the most stable
complexes with Zn2+ were those containing a Histidine residue
close to or at the N terminus and with a free a amino group. The
peptidewith the sequence of ISF402 reversed, DTHV amide, bound
Zn2+ very poorly suggesting that separation of theHistidine residue
from the N terminal a amino group also results in poorer binding.
Ion Trap Electro Spray Ionization Mass Spectrometry was used to
detect the presence of peptide Zn2+ complexes and provide an
indication of stoichiometry (Fig. 1G and H and Table 1). All
histidine containing Zn2+ binding peptides bound Zn2+ in a 1:1 to
ratio and, of these peptides, those containing aspartic acid also
formed complexeswith a 2:1 peptide:Zn2+ stoichiometry (Table 1).
Of all the peptides tested, the tripeptide HTD amide alone
displayed 1:1 and 2:1 HTD:Zn2+ adducts that were more
predominant than the remaining monomeric peptide (m/
z = 371.01); illustrated by the clusters at m/z = 432.95 and
803.12, respectively (Fig. 1H). HTD amide also demonstrated a
propensity to form soluble multimers ranging in size from
monomer to tetramer, but these multimers were not detectable
Fig. 1. Representative data of CD and ESI-MS screening of peptide analogs for Zn2+ binding potential. (A–F) CD spectra displaying blank (solid line), peptide alone (dashed line)
and peptide + Zn2+ (dotted line) samples. Peptide concentration = 100 mM, Zn2+ concentration = 200 mM. (A) VHTD-amide binds Zn2+ as evidenced by signiﬁcant decrease in
CD (mdeg) at 220 nm. (C) HTD-amide also binds Zn2+ as evidenced by signiﬁcant decrease in CD (mdeg) at 220 nm. (B and D) Ac-VHTD-amide and Ac-HTD-amide do not
signiﬁcantly bind Zn2+ as illustrated by the coincidence of both spectra. (E) Negative control ARSE-amide does not bind Zn2+ due to the absence of Zn2+ binding amino acid
residues; both spectra are perfectly superposed. (F) Positive control GHSE-amide does bind Zn2+ due to the inclusion of Histidine, although not as well as VHTD-amide as
evidenced by 50% less change in CD at 220 nm. (G and H) Ion-Trap ESI-MS spectra of HTD-amide  Zn2+. (G) Ion-Trap ESI-MS of HTD-amide alone at pH 7.0 reveals
multimerization to dimers, trimers and least stably, tetramers. (H) Conversely, in the presence of Zn2+, 1:1 and 2:1 HTD:Zn2+ complexes are readily detectable at pH 7.0.in the presence of Zn2+ (Fig. 1G). GHSE amide was used as a
positive control andwas found to form a stable 1:1 Zn2+ adduct but
not as efﬁciently as HTD amide/GHTD amide and VHTD amide
(Fig. 1F and Table 1). The pH dependence of zinc bindingwas tested
using ISF402 at 1 mg/ml dissolved in deionized water with pH
adjustment using sodium hydroxide and measurement of the
change in CD signal at 220 nm (Table 2). The reduction in thenegative peak at 220 nm was only apparent at pH 6 or higher,
which is consistent with the deprotonation of histidine aiding zinc
complex formation.
Potentiometric titration of HTD amide was performed to
determine the stoichiometry of Zn2+ binding (Fig. 2). Addition of
Zn2+ to give a 1:1 HTD:Zn ratio produced a profound shift in the
titration curve which is consistent with strong binding. The
Table 1
Circular dichroism and Electro-Spray Ionization Mass Spectrometry screening of
peptide analogs for Zn2+ binding potential.
Peptide DCD
220 nm
ESI-MS M* Multimers Zn2+ complex
(peptiden:Zn
2+
n)
HTD-amide ++ 371.20 n = 1 > 2 > 3 > 4 1:1 > 2:1 (++)
GHTD-amide ++ 428.19 n = 1 > 2 1:1 > 2:1 (++)
VHTD-amide ++ 471.21 n =1 > 2 1:1 > 2:1 (++)
Ac-HTD-amide  413.18 n = 1 1:1 (+)
Ac-VHTD-amide  512.25 n = 1 1:1 (+)
VHTD-OH ++ 471.21 n = 1 > 2 1:1 > 2:1 (++)
VHT-amide ++ 355.21 n = 1 1:1 (+)
DTHV-amide + 470.23 n = 1 1:1 > 2:1 (+)
VVTD-amide  432.24 n = 1 > 2 –
VHTN-amide ++ 469.24 n = 1 1:1 (++)
VHAD-amide ++ 440.22 n = 1 > 2 1:1 > 2:1 (++)
ARSE-amide  461.25 n = 1 > 2 –
GHSE-amide ++ 428.18 n = 1 1:1 (++)
For description of CD++ ,+, = marked (>2 mdeg), signiﬁcant (<2 mdeg) and absent
DCD, respectively. Similarly, when describing ESI-MS++, +,  = marked (Zn2+
adduct > 20% M*), signiﬁcant (Zn2+ adduct < 20% M*), and absent (no Zn2+ adducts
observed) zinc binding peak intensities, respectively. The series of multimers from
monomer to tetramer are represented by n = 1, . . ., 4.
Table 2
The effect of pH on ISF402/zinc interactions.
pH CD signal ([mdeg]) at
220 nm in the
absence of Zn2+
CD signal ([mdeg]) at
220 nm in the presence
of 2 mM Zn2+
3 2 2
4 0 0
5 5 1
6 5 13
7 0 25
Fig. 3. Representative determination of equilibrium dissociation constant (KD) for
binding of HTD-amide to Zn2+. (A) Figure showing the increase in ellipticity of
25mM HTD-amide as a function of increasing Zn2+ concentration (path-length
(l) = 10 mm). The CD values for each spectra are measured at 220 nm and used to
construct a saturation binding curve. (B) The saturation binding curve was
constructed and analyzed as described in experimental procedures. An excellent ﬁt
to the data was obtained assuming a 1:1 peptide:Zn binding model (shown by the
solid line). KD was determined to be 2.3  0.3 mM.magnitude of this shift was essentially halved for solution with a
2:1 HTD:Zn ratio and thereafter, further decreases in Zn2+
concentration induced little change in the titration proﬁle of
HTD. This veriﬁes the ﬁndings of Ion Trap ESI MS that the
predominant HTD:Zn complex has a stoichiometry of 1:1.
The interaction between the peptides and zinc was concentra
tion dependent as shown by the magnitude of the change in CD at
220 nm with increasing Zn2+ concentration (Fig. 3A). This allowed
determination of the equilibrium dissociation constant (KD) for
binding of HTD amide to Zn2+ from the increase in ellipticity as a
function of increasing Zn2+. From the saturation binding curve andFig. 2. Potentiometric titration of HTD-amide for determination of zinc binding
stoichiometry. Titration of HTD-amide alone and in the presence of decreasing
amounts of Zn2+ veriﬁes the ﬁndings of Ion-Trap ESI-MS. The 1:1 HTD:Zn reaction
leads to a profound shift in the titration curve which indicates strong binding. The
magnitude of this shift is essentially halved for 2:1 HTD:Zn. Thereafter, further
decreases in [Zn2+] induces only minor changes in the titration proﬁle of HTD. The
titration curves for HTD:Zn mixtures terminate at pH 8.5 due to the formation of
insoluble zinc hydroxides at higher pHs.assuming a 1:1 stoichiometry (Fig. 3A) theKDwas determined to be
2.3  0.3 mM at pH 7.4 in water. Similar analysis performed for
GHTD amide and ISF402 revealed KDs of 15.9  4.3 and 42.9  13.1,
respectively.
3.2. Dispersal of insulin hexamers by ISF402
Insulin forms hexameric complexes that are stabilized by zinc
ions and these complexes can be dispersed by zinc binding agents.Fig. 4. Near- and far-UV CD spectra of humalin (2Zn–insulin) and the effect of HTD.
Solid line (—) = blank, dashed line (- - -) = 100mM 2Zn–insulin, dotted line
(  ) = 100 mM 2Zn–insulin + 66 mM HTD-amide. The main ﬁgure illustrates the
decrease in ellipticity in the far-UV that accompanies conversion of the hexamer to
dimer/monomer due to the addition of HTD-amide, namely; decreases in ellipticity
at 217 and 222 nm. The near-UV spectra (inset) reﬂects the same phenomenon;
reduction in ellipticity at 275 nm and conversion of the hexamer to dimer/
monomer due to the addition of HTD-amide.
The ability of GHTD amide and ISF402 to disperse hexameric
insulin was examined by CD and size exclusion chromatography.
Hexamer to dimer transitions of insulin can be studied using
near and far UV circular dichroism [15]. Fig. 4 illustrates the
decrease in ellipticity in the far UV that accompanies conversion of
the insulin hexamer to dimer/monomer due to the addition of
HTD amide. Characteristic decreases in ellipticitywere apparent at
both 217 and 222 nm. The near UV spectra (Fig. 4, inset) reﬂect the
same phenomenon with a reduction in ellipticity at 275 nm.Fig. 5. GHTD-amide and ISF402 cause dissociation of insulin hexamers. Size exclusion
performed in the presence of 60 mM zinc under conditions where the hexameric insuli
276 nm, which detects insulin, and 214 nm, which detects both insulin and peptides. Ab
zinc insulin elutes at 13–15 ml. (B) Insulinmixed with non-chelating peptide (NCP) has a
with GHTD-amide, and (D) insulin mixed with ISF402 show reductions in the size and
correspond to dimeric and monomeric insulin (E).GHTD amide caused similar changes in ellipticity of hexameric
insulin solutions (data not shown).
For size exclusion chromatography, the concentration of human
insulin was maintained at 1 mg/ml (pH 7.4) as at this concentration
insulin exists predominantly as Zn2+ dependent hexamers. Mon
itoring of the eluate at 276 nm detected an absorbance due to a
tyrosylgroupwhichwasattributable to insulin,whereasboth insulin
and thepeptidesaredetected at 214 nm.Human insulin aloneeluted
as hexameric insulin with a single peak at 13.32 ml (Fig. 5A).chromatography of hexameric insulin and mixtures of insulin and peptide were
n and peptides remain in contact within the gel matrix. Elution was monitored at
sorbance at 276 nm was negligible for all peptides (data not shown). (A) Hexameric
similar proﬁle to insulin without peptide (absorbance at 276 nm), (C) insulin mixed
broadening of the hexameric insulin peak and the appearance of later peaks that
Monitoring of the elution of insulin and a control non chelating
peptide (NCP) at 276 nm (Fig. 5C) shows that the peak at 13.21
14.09 ml consists of hexameric insulin and there is no dimeric or
monomeric insulin present. Monitoring at 214 nm (Fig. 5B, right
panel) showed the hexameric insulin peak and the non chelating
peptidewhich eluted at 18 20min. These resultswere conﬁrmedby
measurementofprotein concentrationbytheBradfordmethod(data
not shown). In the presence of GHTD amide the amount of
hexameric insulin was reduced as shown by the reduction and
broadening of the peak at 13.39 13.95 ml (Fig. 5C). A minor peak
appeared at 15.09 ml and a major peak at 19.05 ml, which
correspond to dimeric insulin (11.8 kDa) and monomeric (5.8 kDa)
insulin, respectively (Fig. 5C). Monomeric insulin co elutedwith the
GHTD amide and the magnitude of the hexameric insulin peak
detected at 214 nm was also reduced (Fig. 3C, right panel). Similar
results were observed for ISF402 (Fig. 5D).
3.3. Potentiation of insulin activity by GHTD amide and ISF402
Insulin potentiation by GHTD amide and ISF402 was tested in
Zucker fa/fa rats using intravenous insulin tolerance testing.
Insulin resistance in the Zucker fa/fa rats was apparent from the
small reduction in blood glucose after injection of 1 U/kg of
hexameric zinc insulin (Fig. 6A). Injection of insulin mixed with
either GHTD amide or ISF402 at a dose of 1.5 mg/kg signiﬁcantly
decreased blood glucose in comparison to injection of hexameric
zinc insulin alone (Fig. 6A and B). ISF402 was more potent than
GHTD amide in that it caused a greater reduction in the AUC for the
glucose concentration time course (p < 0.005, Fig. 6B). Serum
insulin concentrations were higher 10 min after injection of
insulin/peptide mixtures compared to insulin injected controls
(Fig. 6C). This was most pronounced for ISF402 where insulinFig. 6.GHTD-amide and ISF402 potentiate insulin activity. Intravenous injection of insulin
ﬁlled circles, solid line) or 1 U/kg insulin alone (n = 8, open circle, dotted line) in female Z
bars represent standard error of the mean. The effect of GHTD-amide and ISF402 on glu
Area under the concentration time curves (AUC) for the data shown in A, C and E. The A
ISF402 the AUC insulin was signiﬁcantly increased compared to control (*p < 0.01, Stuconcentrations 10 min after injection were 10 fold higher than
after injection of insulin alone. The peak of serum insulin was
attributable to the injected insulin since C peptide levels were
decreased by each of the insulin/peptide mixtures (Fig. 6E). In
contrast, there was a moderate increase in serum C peptide after
injection of insulin alone.
3.4. Insulin potentiation with monomeric lispro insulin
Lispro insulin, which does not form zinc stabilized hexamers,
was used to test whether insulin potentiation by ISF402 was
related to zinc chelation and dispersal of insulin hexamers. Lispro
insulin or hexameric bovine insulin and 1.5 mg/kg ISF402 were
injected intravenously into Zucker fa/fa rats and insulin sensitive
Sprague Dawley rats. For Zucker fa/fa rats the insulins were used
at 1 U/kg body weight whereas for Sprague Dawley rats, which
are not insulin resistant, the amount of insulin injected was
reduced to 0.5 U/kg in order to minimize hypoglycemia. The area
under the curve (AUC) for the blood glucose time proﬁles over
60 min were calculated (Fig. 7A). Blood glucose time proﬁles are
shown in Figs. 7B and C. In Zucker rats each of the treatments
(ISF402 + hexameric insulin, lispro, and ISF402 + lispro) signiﬁ
cantly reduced blood glucose compared to hexameric insulin
alone and the combination of lispro with ISF402 had the greatest
glucose lowering effect (Fig. 7A). In Sprague Dawley rats, all
treatments signiﬁcantly reduced blood glucose but there was no
additive effect of ISF402 and lispro insulin apparent. The blood
glucose time proﬁles for hexameric insulin with ISF402 and lispro
insulin both with and without ISF402 were all similar with
maximum reductions in blood glucose occurring more rapidly in
Sprague Dawley rats (by 15 min after injection) than in Zucker
rats (Fig. 7C).(1 U/kg)with 1.5 mg/kg GHTD-amide (n = 6, triangles, dashed line) or ISF402 (n = 6,
ucker fa/fa rats. (A) Blood glucose, (C) insulin, (E) C-peptide concentration. The error
cose, insulin and C-peptide were signiﬁcant (p < 0.001, 2 way ANOVA). (B, D and F)
UC for glucose and C-peptide were signiﬁcantly reduced for both peptides and for
dent’s t-test).
Fig. 7. Insulin potentiating activity of ISF402 is reducedwhen combinedwithmonomeric insulin. (A) The area under the curve over 60 min for the blood glucose time proﬁles
of Zucker (black bars) and Sprague–Dawley (white bars) rats after injection of hexameric or lispro insulin and ISF402. (B) The blood glucose proﬁles for female Zucker rats
injected with lispro insulin (n = 5) and lispro with ISF402 (n = 5). The proﬁles for hexameric insulin in Zucker rats are shown in Fig. 1A and C. The blood glucose proﬁles for
Sprague–Dawley rats injected with hexameric insulin (n = 8), hexameric insulin with ISF402 (n = 8), lispro insulin (n = 7), and lispro with ISF402 (n = 9). The error bars
represent standard error of the mean.4. Discussion
GHTD amide was originally puriﬁed from human urine as a
peptide with insulin potentiating activity [17,18]. Here we show,
using a variety of in vitro and in vivo systems, that GHTD amide,
HTD amide and an analog VHTD amide (ISF402) are zinc
chelating peptides that inﬂuence the oligomeric state of insulin
in vitro, and that ISF402 enhances insulin mediated blood
glucose reductions in insulin resistant rats, and that at
least part of the insulin potentiation attributable to the
tetrapeptides may be explained by accelerated dispersal of
insulin hexamers.
GHTD amide and ISF402 are likely to be zinc binding peptides
since they contain histidine, which is often involved in co
ordinating Zn2+, and aspartic acid, which can also contribute to zinc
binding [24]. Generally, tetrapeptides lack secondary structure due
to their small size, but interactions with zinc can induce
conformational changes [10]. The CD proﬁle of GHTD amide and
ISF402 in the presence of zinc was very similar to that previously
described for short alpha helices in peptides [4]. The presence of
histidine and an adjacent freea amino group were found to be the
primary determinants of zinc binding and the change in ellipticity
at 220 nm for these peptides was concentration dependent.
Estimation of dissociation constants was 2.28mM for HTD amide
and 15.9 and 42.9 mM for the tetrapeptides GHTD amide andISF402, respectively. These dissociation constants are close to the
free Zn2+ ion concentration normally found in plasma, which is of
the order of 10 15 mM [13], and so may well have physiological
relevance.
Insulin hexamer formation proceeds by the combination of
three dimers with two zinc ions through interactions with the
histidine residues at position 10 of the B chains [9,7]. In vivo,
insulin biosynthesis occurs within the beta cells of the pancreas
where proinsulin is sequestered within Zn2+ and Ca2+ rich
storage/secretory vesicles and assembled into Zn2+ and Ca2+
containing hexamers. Upon acidiﬁcation of the secretory granule,
proinsulin is converted to insulin and C peptide by proteolytic
enzymes and this signiﬁcantly lowers the solubility of the insulin
hexamer, causing crystallization within the vesicle [6]. The
propensity for insulin to form stable hexameric complexes with
zinc ions has been exploited since the 1930s to produce slow acting
formulations of insulin for treatment of diabetes. More recently,
fast acting insulins have been developed by substituting amino
acids that co ordinate and stabilize hexameric insulin complexes
to produce dimeric/monomeric forms that are more rapidly
released from the injection site into the circulation [12]. The
dissociation of hexameric zinc insulin into monomers is hypothe
sized to be a rate limiting step in the systemic absorption of insulin
from a subcutaneous injection site [5] and zinc chelating agents
increase the rate of dispersal of hexameric insulin in vitro [8,11]. It
has also been proposed that in vivo an endogenous Zn2+ chelator is
required for sufﬁciently rapid dispersal of hexameric insulin upon
release from beta cell secretory granules [8].
In this study we have shown the loss of hexameric and the
formation of dimeric and monomeric insulin species when
GHTD amide or ISF402 were present but not when a non
chelating peptide was used. Dispersal of insulin hexamers by
GHTD amide was conﬁrmed by near UV circular dichroism [16].
From these results it can be concluded that GHTD amide and
ISF402 are zinc binding peptides that can disperse zinc
stabilized hexamers of insulin. This prompted us to explore in
vivo the effect of the peptides on insulin mediated glucose
disposal.
GHTD amide and ISF402 enhanced reductions in blood glucose
levels when combined with insulin and altered the serum insulin
time proﬁles causing a large peak in serum insulin early in the
time course that was not apparent in controls. This was not due to
stimulation of endogenous insulin secretion as serum C peptide
was signiﬁcantly decreased, which is indicative of reduced
pancreatic insulin release.
A relationship between dissolution of hexameric insulin and
insulin potentiation was shown using ISF402 and co injection
with lispro insulin. In lispro insulin the Pro and Lys at position
B28 and B29 are reversed so hindering the formation of dimers,
which are an intermediate step in hexamer formation. The
monomeric property of lispro insulin in vivo enables its use in
the treatment of diabetes as a fast acting insulin analog. While in
Zucker rats there were some further reductions in blood glucose
when ISF402 was combined with lispro, in Sprague Dawley rats
co injection of ISF402 with lispro insulin did not cause further
reductions in blood glucose concentrations. This data is
consistent with ISF402 interacting with injected hexameric
insulin to promote the formation of monomeric insulin. We
propose a model for the action of HTD amide peptides in which
the zinc ion is chelated from the exposed core of the zinc insulin
hexamer causing its destabilization and rapid dispersal to
monomers. When ISF402 is present, the insulin hexamers
disperse so that the insulin monomers are free to bind to
receptors, however, when lispro insulin is used in place of
hexameric zinc insulin this effect is not observed as lispro
insulin is already in monomeric form. Notably, injection of 1 U/
kg body weight of lispro insulin alone caused a greater reduction
in blood glucose and C peptide concentration than did 1 U/kg
body weight of hexameric insulin, consistent with the notion
that monomeric insulin acts more rapidly than hexameric
insulin after intravenous injection. A similar function for C
peptide in disaggregating hexameric complexes of insulin at the
site of subcutaneous injection has previously been proposed
[22]. Implicit in our ﬁndings is that insulin hexamers take some
minutes to disperse upon dilution in blood. Testing this directly
would require direct measurement of the behavior of insulin
oligomers in blood, which is limited by the complexity of blood
as a matrix and its incompatibility with available technology for
determining oligomeric states of insulin. Regardless, the
presence of endogenous GHTD amide in pancreatic beta cells
[19] and its ability to chelate Zn2+ and disperse hexamers of
insulin as demonstrated here make GHTD amide a candidate for
the endogenous chelator that is hypothesized to ensure rapid
dispersal of beta cell hexameric insulin upon release into the
circulation [8].
Our previous studies have shown that GHTD amide potently
stimulates glycogen synthesis in cultured liver and muscle cell
lines, and that this activity was not dependent on the addition of
insulin to the culture media [19]. Hence GHTD amide appears to
have two activities that promote glucose disposal, rapid dispersal
of hexamers of insulin through zinc chelation and a directstimulation of glucose disposal through stimulation of glycogen
synthesis. The greater reduction in glucose in Zucker rats injected
with ISF402 and lispro insulin compared to injection of insulin
alone may be due to this insulin independent stimulation of
glycogen synthesis.
In conclusion, we have shown that GHTD amide and ISF402
are zinc binding peptides that disperse hexameric insulin in vitro
and that in vivo enhancement of insulin activity is reduced or
absent when monomeric lispro insulin is used. These
results suggest that dispersal of zinc stabilized insulin hexamers
accounts in part for the insulin potentiating activity of
these peptides. GHTD amide and ISF402 may prove useful
as therapeutic treatments for diabetes by optimizing the
activity of injected and endogenous insulin in the insulin
resistant state.
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